CD79A and COVID-19: Rajamanickam’s study (13) quantitatively evaluated serum levels of IgM, IgG, IgA and neutralizing antibodies specific against SARS-CoV-2, finding that all were elevated in patients with COVID-19 and LTBI compared to patients with only COVID-19.